Payment overview · 2025
General Payments
$416.36
11 reported records · 7 companies
Healthcare provider profile · identity verified
Venus Nguyen
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · EL CENTRO, CA · NPI 1053705087
Verified facts
What the public records show
CMS Open Payments records show Venus Nguyen received $416.36 in general payments during 2025 across 11 reported records.
AstraZeneca Pharmaceuticals LP accounted for 39.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $163.53 | 39.3% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $88.57 | 21.3% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $64.61 | 15.5% | 2 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $36.52 | 8.8% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $24.10 | 5.8% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $21.65 | 5.2% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $17.38 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $416.36 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $104.17 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $88.57 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $64.61 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.33 | 2 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $36.52 | 1 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $20.03 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $17.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 65 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
65 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
114 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
34 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 369 | 199 |
| Metformin Hcl | Metformin Hcl | 283 | 152 |
| Omeprazole | Omeprazole | 256 | 139 |
| Gabapentin | Gabapentin | 229 | 133 |
| Losartan Potassium | Losartan Potassium | 224 | 125 |
| Amlodipine Besylate | Amlodipine Besylate | 181 | 106 |
| Lisinopril | Lisinopril | 177 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 167 | 94 |
| Meloxicam | Meloxicam | 152 | 95 |
| Ibuprofen | Ibuprofen | 132 | 95 |
| Baclofen | Baclofen | 128 | 85 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 61 |
| Lidocaine | Lidocaine | 121 | 63 |
| Trazodone Hcl | Trazodone Hcl | 118 | 56 |
| Ozempic | Semaglutide | 114 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 112 | 61 |
| Alendronate Sodium | Alendronate Sodium | 109 | 62 |
| Prednisone | Prednisone | 109 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 108 | 50 |
| Tramadol Hcl | Tramadol Hcl | 108 | 49 |
| Potassium Chloride | Potassium Chloride | 98 | 51 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 86 | 51 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 44 |
| Simvastatin | Simvastatin | 82 | 42 |
| Carvedilol | Carvedilol | 78 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 78 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 37 |
| Sucralfate | Sucralfate | 72 | 42 |
| Furosemide | Furosemide | 70 | 50 |
| Glimepiride | Glimepiride | 69 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 39 |
| Farxiga | Dapagliflozin Propanediol | 65 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 29 |
| Azithromycin | Azithromycin | 63 | 59 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 62 | 47 |
| Sertraline Hcl | Sertraline Hcl | 58 | 33 |
| Doxycycline Hyclate | Doxycycline Hyclate | 54 | 54 |
| Montelukast Sodium | Montelukast Sodium | 53 | 28 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 50 |
| Finasteride | Finasteride | 51 | 21 |
| Linzess | Linaclotide | 50 | 25 |
| Jardiance | Empagliflozin | 49 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 46 | 29 |
| Alprazolam | Alprazolam | 45 | 26 |
| Naproxen | Naproxen | 45 | 25 |
| Tradjenta | Linagliptin | 45 | 24 |
| Hydralazine Hcl | Hydralazine Hcl | 44 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 42 | 27 |
| Naloxone Hcl | Naloxone Hcl | 42 | 33 |
| Varenicline Tartrate | Varenicline Tartrate | 42 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 37 |
| Bumetanide | Bumetanide | 40 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 26 |
| Isoniazid | Isoniazid | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 16 |
| Meclizine Hcl | Meclizine Hcl | 36 | 27 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 36 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 35 | 22 |
| Rybelsus | Semaglutide | 34 | 16 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | 11 |
| Buspirone Hcl | Buspirone Hcl | 33 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Donepezil Hcl | Donepezil Hcl | 32 | 19 |
| Clonazepam | Clonazepam | 31 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 24 |
| Famotidine | Famotidine | 30 | 15 |
| Benazepril Hcl | Benazepril Hcl | 29 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 14 |
| Fluconazole | Fluconazole | 27 | 21 |
| Metformin Hcl Er | Metformin Hcl | 27 | 20 |
| Ondansetron Odt | Ondansetron | 27 | 23 |
| Icosapent Ethyl | Icosapent Ethyl | 26 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | 16 |
| Nystatin | Nystatin | 24 | 17 |
| Bupropion Xl | Bupropion Hcl | 23 | 11 |
| Eliquis | Apixaban | 23 | 16 |
| Nifedipine Er | Nifedipine | 23 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | 16 |
| Glipizide | Glipizide | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | 12 |
| Lorazepam | Lorazepam | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | 15 |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Pregabalin | Pregabalin | 20 | 12 |
| Trulicity | Dulaglutide | 20 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | 12 |
| Cephalexin | Cephalexin | 18 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 17 |
| Nitroglycerin | Nitroglycerin | 18 | 14 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 17 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | 11 |
| Loperamide | Loperamide Hcl | 17 | 15 |
| Memantine Hcl | Memantine Hcl | 17 | 14 |
| Peg-3350 And Electrolytes | Peg3350/Sod Sulf,bicarb,cl/Kcl | 17 | 17 |
| Allopurinol | Allopurinol | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | 11 |
| Gentamicin Sulfate | Gentamicin Sulfate | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | 11 |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | 11 |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 13 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | 11 |
| Hydrocortisone | Hydrocortisone | 13 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $416.36 · 11 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, APTIMA, AREXVY, FARXIGA, REZDIFFRA, SHINGRIX, TEZSPIRE, Veozah, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error